BioHive

2 known investors

BioHive develops skin organoid technology derived from iPSCs, offering customizable organoids with multiple cell types for toxicity, efficacy, and inflammatory analysis. It serves the pharmaceutical and dermo-cosmetic industries to reduce R&D costs and reliance on animal models.